Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced that its subsidiary Cana Laboratories signed a manufacturing and supply agreement to produce the finished pharmaceutical PathMuscle for Libytec Pharmaceutical S.A., the product's exclusive distributor in Greece, effective Jan 5, 2026. Cosmos Health will handle end-to-end production, quality control, and product release for multiple oral presentations (film-coated and soluble tablets).

The deal includes a firm minimum of 591,500 units and expected cumulative volumes of over 1.2 million units across five years, intended to improve capacity utilization and provide enhanced revenue visibility, subject to market demand and commercial performance.

Positive

• Firm minimum committed volume: 591,500 units
• Expected five-year volumes: >1.2 million units
• End-to-end manufacturing responsibility increases operational control
• Agreement aims to improve capacity utilization
• Enhances near-term revenue visibility for pharmaceutical operations

Negative

• Five-year volume projection is subject to market demand
• Distribution limited to the Greek market, limiting geographic reach

Argus Jan 5 session

+3.05% close to close Open Argus

Details

News Market Reaction – COSM

On Jan 5, the day this news came out, COSM closed 3.05% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Market Context

This announcement establishes Cosmos Health as the end-to-end manufacturer of PathMuscle for Libytec...

Analysis

This announcement establishes Cosmos Health as the end-to-end manufacturer of PathMuscle for Libytec, backed by firm minimum volumes of 591,500 units and expected five-year output above 1.2 million units. It reinforces the company’s vertically integrated model alongside earlier record $17.11M quarterly revenue and digital asset initiatives. Investors may track execution on committed volumes, any follow-on manufacturing deals, and how this contract influences capacity utilization and revenue visibility.

Key Figures

Five-year expected volume: 1.2 million units Minimum committed volume: 591,500 units Thiocolchicoside dose (tablet): 2 mg +5 more

Five-year expected volume

1.2 million units

Expected cumulative PathMuscle production over five years, subject to demand

Minimum committed volume

591,500 units

Firm minimum PathMuscle production under Libytec agreement

Thiocolchicoside dose (tablet)

2 mg

Per film-coated PathMuscle tablet

Paracetamol dose (tablet)

500 mg

Per film-coated PathMuscle tablet

Thiocolchicoside dose (soluble)

4 mg

Per soluble PathMuscle tablet

Paracetamol dose (soluble)

1,000 mg

Per soluble PathMuscle tablet

Film-coated pack size

30 tablets

Alu/PVC blister pack for film-coated tablets

Soluble pack size

20 tablets

Alu/PVC blister pack for soluble tablets

Historical Context

5 past events · Latest: Dec 24

5 events

1. Dec 24

   Operations & strategy

   24h Move

   +1.1%

   Q3 revenues above $17M and tariff-mitigation via added U.S. manufacturing capacity.

2. Dec 19

   Earnings & strategy

   24h Move

   -4.0%

   Record quarter with revenue above $17M, margin expansion, and Ethereum purchases.

3. Dec 03

   Treasury partnership

   24h Move

   -10.8%

   Prime Ledger partnership to manage $300M digital asset treasury and tokenize IP.

4. Dec 02

   Insider buying

   24h Move

   -2.2%

   CEO added 3.4M shares YTD alongside record-breaking Q3 revenue and margins.

5. Nov 17

   Record earnings

   24h Move

   -3.1%

   Revenue up 38% to $17.11M, gross profit up 116%, margin at 15.21%, cash up to $4.63M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

thiocolchicoside, paracetamol, acetaminophen, analgesic, +4 more

8 terms

thiocolchicoside medical

"fixed-dose combination of thiocolchicoside, a centrally acting muscle relaxant"

Thiocolchicoside is a prescription muscle relaxant used to relieve painful muscle spasms; think of it as a targeted tool that calms overactive muscles so patients can move and recover more easily. For investors, it matters because its approval status, safety warnings, or supply changes can directly affect a drug maker’s sales, legal exposure, and regulatory costs—similar to how a popular product recall could swing a consumer company’s revenue and reputation.

paracetamol medical

"thiocolchicoside, a centrally acting muscle relaxant, and paracetamol (acetaminophen)"

An over-the-counter pain reliever and fever reducer commonly known as paracetamol (acetaminophen) used worldwide for headaches, aches and fevers. Investors care because it is a high-volume, low-margin pharmaceutical staple whose sales, manufacturing costs, safety issues, supply shortages, regulatory actions or generic competition can quickly affect a drugmaker’s revenue and reputation — much like a basic, everyday product that anchors a company’s steady cash flow.

acetaminophen medical

"muscle relaxant, and paracetamol (acetaminophen), an analgesic and antipyretic agent"

Acetaminophen is a widely used pain reliever and fever reducer that serves as the main active ingredient in many over‑the‑counter and prescription medicines. Investors care because its safety profile, supply availability, regulatory limits, or product recalls can directly affect sales, manufacturing costs and brand trust for drug makers and retailers—much like a staple ingredient in a recipe shaping the final product’s marketability.

analgesic medical

"paracetamol (acetaminophen), an analgesic and antipyretic agent"

An analgesic is a medication that reduces or eliminates pain without putting a person to sleep, covering common over-the-counter remedies through stronger prescription drugs. For investors, analgesics matter because their safety profile, regulatory approvals, patent protection and broad or limited use determine sales potential, liability exposure and long-term profits—think of them as either everyday household staples or specialized tools that drive revenue and risk.

antipyretic medical

"paracetamol (acetaminophen), an analgesic and antipyretic agent"

A medication that lowers fever by reducing the body’s temperature, like a thermostat that brings an overheated system back toward normal. Investors care because antipyretics are common over‑the‑counter and prescription products whose safety profile, regulatory approvals, patent status and supply chain can affect a healthcare company’s sales, liability risk and growth prospects; changes in demand or regulation can influence stock value.

musculoskeletal medical

"designed to address musculoskeletal conditions by providing both muscle-relaxant activity"

Musculoskeletal relates to the system of bones, muscles, joints, and tissues that support and move the body. It is important to investors because issues or changes in this system can impact the health and productivity of individuals, potentially affecting industries such as healthcare, pharmaceuticals, and insurance. Understanding musculoskeletal health helps gauge broader trends in healthcare spending and workforce well-being.

film-coated tablets technical

"approved in multiple oral presentations, including film-coated tablets containing"

Film-coated tablets are solid pills coated with a thin polymer layer that protects the medicine, masks taste, and controls how the tablet dissolves in the body—think of a candy shell that keeps the center intact until the right time. For investors, the coating can affect a drug’s delivery, shelf life, regulatory classification and manufacturing complexity, which in turn influence production costs, pricing, and marketability.

Alu/PVC blister packs technical

"supplied in 30-tablet Alu/PVC blister packs, as well as soluble tablets"

Alu/PVC blister packs are a common drug packaging format consisting of individual plastic pockets (PVC) that hold pills or capsules, sealed on the back with a thin sheet of aluminum foil. They keep doses separate, protect medicines from moisture and light, and provide tamper-evidence; for investors, the choice of this packaging affects product shelf life, regulatory compliance, manufacturing cost and supply-chain reliability—think of it like an egg carton and foil wrapper that preserves and organizes each dose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece.

Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements.

PathMuscle is an advanced generic pharmaceutical product formulated as a fixed-dose combination of thiocolchicoside, a centrally acting muscle relaxant, and paracetamol (acetaminophen), an analgesic and antipyretic agent. The combination is designed to address musculoskeletal conditions by providing both muscle-relaxant activity and pain relief within a single dosage form.

PathMuscle is approved in multiple oral presentations, including film-coated tablets containing thiocolchicoside 2 mg and paracetamol 500 mg, supplied in 30-tablet Alu/PVC blister packs, as well as soluble tablets containing thiocolchicoside 4 mg and paracetamol 1,000 mg, supplied in 20-tablet Alu/PVC blister packs, and is indicated for the symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders.

The product will be distributed and commercially promoted in the Greek market by Libytec Pharmaceutical S.A., with the agreement providing for firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units, subject to market demand and commercial performance.

The agreement reflects Cosmos Health’s vertically integrated pharmaceutical manufacturing capabilities and is expected to support improved capacity utilization and enhanced revenue visibility across its pharmaceutical manufacturing operations.

Greg Siokas, CEO of Cosmos Health, stated: “This agreement supports our strategic focus on expanding pharmaceutical manufacturing through long-term, volume-backed collaborations. By assuming full responsibility for the end-to-end production of PathMuscle, Cosmos Health demonstrates its operational strength, regulatory expertise, and ability to deliver reliable, scalable manufacturing solutions. We believe this collaboration enhances production visibility and reinforces our position as a trusted manufacturing partner in the European pharmaceutical market.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cosmos Health announce on January 5, 2026 regarding PathMuscle (COSM)?

Cosmos Health said its subsidiary Cana Laboratories will manufacture and supply PathMuscle for Libytec, handling complete end-to-end production and release.

How many PathMuscle units did Cosmos Health commit to produce under the COSM agreement?

The agreement includes a firm minimum of 591,500 units and expected cumulative production of over 1.2 million units across five years.

Which PathMuscle formulations will Cosmos Health produce under the COSM deal?

Cosmos Health will produce film-coated tablets (thiocolchicoside 2 mg/paracetamol 500 mg) and soluble tablets (thiocolchicoside 4 mg/paracetamol 1,000 mg).

Where will PathMuscle be distributed under the Cosmos Health manufacturing agreement (COSM)?

Libytec Pharmaceutical will commercially distribute and promote PathMuscle in the Greek market as the product's exclusive distributor there.

How does the PathMuscle agreement affect Cosmos Health's operations and revenue visibility (COSM)?

The company states the volume-backed agreement should improve capacity utilization and provide enhanced revenue visibility for its pharmaceutical manufacturing operations.